Eukaryotic translation initiation factor 4 gamma 1 mRNA (EIF4G1 mRNA)

Eukaryotic translation initiation factor 4 gamma 1 (EIF4G1) mRNA encodes a vital scaffolding protein that serves as a central component of the eIF4F translation initiation complex (UniProt Q04637). This complex is responsible for recruiting the 40S ribosomal subunit to the 5' cap of messenger RNAs, which is a rate-limiting step in protein synthesis (PubMed: 17403358). EIF4G1 facilitates this process by interacting with the cap-binding protein eIF4E, the RNA helicase eIF4A, and the poly(A)-binding protein (PABP), effectively circularizing the mRNA to enhance translation efficiency (PubMed: 22001471). In many human cancers, EIF4G1 mRNA is overexpressed, leading to the preferential translation of mRNAs involved in cell growth, survival, and metastasis, which contributes to tumor progression and chemoresistance (PubMed: 22001471). Targeting EIF4G1 mRNA using antisense oligonucleotides or RNA interference is being explored as a therapeutic strategy to reduce the levels of this potent oncogenic driver and inhibit aberrant translation in disease states. Beyond oncology, mutations in the EIF4G1 gene have been associated with autosomal dominant Parkinson's disease (PARK18), suggesting that the regulation of this mRNA is also critical for maintaining proteostasis and neuronal health (PubMed: 21907011). Additionally, many viruses exploit the EIF4G1 protein by cleaving it to shut down host cell translation while favoring viral protein synthesis, making the EIF4G1 pathway a target for antiviral research (PubMed: 17403358).

Other names

eIF4G1 mRNAeIF-4G1 mRNAp220 mRNAEukaryotic translation initiation factor 4G1 mRNA

Antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs) target the EIF4G1 mRNA sequence to induce its degradation via RNase H or the RNA-induced silencing complex (RISC), respectively, thereby preventing the synthesis of the EIF4G1 protein (PubMed: 22001471).